PROPOSAL SUBMISSION DEADLINES AND AWARD ANNOUNCEMENTS

**Preliminary Application**
Interested applicants are **required to submit a Preliminary Application** through the [UFunds online portal](http://ufunds.org) no later than **Thursday, October 18, 2018 at 5pm ET**. The Preliminary Application must include the following:

1. Contact and academic information as requested via the UFunds application page.
2. Indication of the **award category** to which the investigator is applying.
3. Structured one-page overview of research aims, significance, and approach.
4. References.
5. NIH-formatted **biosketch** for each investigator and mentor.
6. Letter from Department Chair(s) stating postdoctoral fellow or resident physician applicants will have a faculty appointment by May 1, 2019, *if applicable* (not required for current faculty).

A Brown University ID is required to access UFunds. Non-Brown faculty should email [joseph_rego@brown.edu](mailto:joseph_rego@brown.edu) by October 11 to request a Brown University ID to use for this application.

Applicants interested in speaking with Advance-CTR leadership to discuss how to strengthen a preliminary application can request a meeting by contacting [joseph_rego@brown.edu](mailto:joseph_rego@brown.edu) no later than Thursday, October 4, 2018.

Invitations to submit a full proposal will be announced on or around **Friday, November 9, 2018**.

**Final Proposal**
Final proposals must be submitted no later than **Tuesday, December 18, 2018 at 5pm ET** through the [UFunds portal](http://ufunds.org).

Responses to full proposal questions will be posted in a Q&A on the [Advance-CTR website](http://advance-ctr.org).

Pilot Project award announcements are anticipated to be communicated by email to applicants on or around **Thursday, February 21, 2019**.

*Individuals from underrepresented minority groups are encouraged to apply for a Pilot Project.*
AWARD CATEGORIES & ELIGIBILITY REQUIREMENTS

Category 1
To be eligible for a Pilot Project award at $37,500:

1. Applicants must possess health-professional or research doctoral degrees and hold a faculty appointment.
2. The Contact PI should hold a faculty appointment as Instructor or Assistant Professor (or equivalent) with a degree-granting institution in Rhode Island at the time the Pilot Project award commences. More senior faculty who are transitioning to a clinical or translational research focus or who are entering a new area of clinical or translational research can also serve as the Contact PI.
3. Mentor(s) should be designated who are faculty at an Advance-CTR affiliated health care system (Lifespan, Care New England, Providence VAMC) or a degree-granting institution in Rhode Island. Mentor(s) should be researchers in the field related to the proposed project, have experience and demonstrated success as research supervisors, and be faculty at the Associate Professor level or above. Projects may have more than one mentor, such as one who is an expert in the content of the proposed research and another who is an expert in the proposed methodology (e.g., statistics, epidemiology, informatics, etc.).
4. The Contact PI cannot be receiving or have previously received external funding in the role of a PI or co-PI from a R01 or equivalent (e.g., VA Merit Review or NSF grant). Note that Contact PIs with Foundation or Mentored grants are eligible.*
5. A PI cannot hold funding from a COBRE project or another IDeA mechanism of support at the same time as Advance-CTR Pilot Project funding.
6. The proposed Advance-CTR Pilot Project should not have significant scientific or budgetary overlap with another funded project.

*Faculty who have served as PI or co-PI on a prior R01 or equivalent are eligible to serve as Contact PI if proposing a pilot project that is in a new area of clinical or translational research.

Category 2
To be eligible for a Pilot Project award at $75,000, projects must meet all eligibility requirements above and also:

- Be led by two or more Principal Investigators (Multi-PI) from different disciplines or training backgrounds. A Contact PI must be designated. Partnerships from different departments or institutions are encouraged. Trans-institutional collaborations among faculty at Brown University, University of Rhode Island, Rhode Island healthcare institutions, or other degree-granting institutions in Rhode Island are highly encouraged. Multi-PI's can be junior or senior investigators.
- The Contact PI must be a junior investigator or a senior faculty member entering a new area of clinical or translational research, as noted in eligibility requirement #2 above.
- If a Multi-PI is a senior investigator, then this individual could also be a mentor for the project.
- Multi-PIs cannot hold funding from a COBRE project or another IDeA mechanism of support at the same time as Advance-CTR Pilot Project funding.

Questions regarding applicant eligibility should be emailed to joseph_rego@brown.edu.

OVERVIEW
The aim of Advance-CTR is to support both the infrastructure development and resources required to conduct clinical and translational research in Rhode Island in order to enhance collaboration and coordination of state-wide clinical and translational research activities. Advance-CTR seeks to connect researchers and support institutions across Rhode Island with the common goal of advancing clinical and translational research that ultimately improves population health in the state. Through its interdisciplinary model, Advance-CTR supports research along the translational science spectrum, including basic science, clinical, and public health efforts, to improve the health of Rhode Island residents.
The Advance-CTR Pilot Projects Program seeks to identify talented young investigators who are new to clinical and translational research and based at Brown University, University of Rhode Island, an affiliated health care system (Lifespan, Care New England, Providence VAMC), or another degree-granting institution in Rhode Island. The Pilot Projects Program also aims to support new collaborations among investigators. Pilot projects will be funded for one year, with the potential for a competitive renewal for a second year of funding.

For the purpose of this Program, clinical and translational research are defined below:

**Clinical research** comprises research with human subjects that is:
- Patient-oriented research. Research conducted with human subjects (or on material of human origin such as tissues, specimens, and cognitive phenomena) for which an investigator directly interacts with human subjects. Excluded from this definition are *in vitro* studies that utilize human tissues that cannot be linked to a living individual.
- Epidemiological and behavioral studies.
- Outcomes research and health services research.

**Translational research** aims to convert basic research advances to practical applications in humans and/or research aimed at the adoption of best practices in community health care.

**Funding Available**
The 2018 Pilot Projects Program will fund five to eight pilot projects for one-year research grants. Indirect costs associated with the direct costs will be provided to the applicants’ home institutions.

**Category 1:** Proposals with a single PI may apply for up to $37,500 direct costs.

**Category 2:** Proposals involving at least two PIs (e.g., Multi-PI’s) from different disciplines may apply for up to $75,000 direct costs. A Contact PI who is a junior investigator or a senior faculty member transitioning to a new area of clinical or translational research must be designated.

**Performance Period**
The anticipated performance period is 5/1/2019 to 4/30/2020.

**Available Services for Applicants**
All applicants are strongly encouraged to schedule a consultation with the Advance-CTR Service Cores (Biostatistics and Research Design, Biomedical Informatics, and Clinical Research Resources) to enhance their responsiveness to this RFA. Applicants are encouraged to review available services on the Advance-CTR website and submit service requests for any inquiries.

**Special Considerations**
While the best science will be prioritized, special consideration, in no particular order, will be given to investigators who:

1. Pursue research that addresses health problems prioritized by the Rhode Island Department of Health. Priority areas (in no particular order) include, but are not limited to:
   - Chronic illnesses (e.g., diabetes, heart disease, asthma, cancer)
   - Health of mothers and their children
   - Substance use
   - Obesity
   - Senior health
   - Behavioral health and wellness
   - Recovery and rehabilitation
   - Pediatric/perinatal care
   - Communicable diseases (HIV, Hepatitis C)

2. Incorporate community engagement into their proposed research when appropriate. For the purpose of the Pilot Projects Program, Advance-CTR utilizes the CDC-supported definition of community engagement:
**Community engagement** is the process of working collaboratively with and through groups of people affiliated by geographic proximity, special interest, or similar situations to address issues affecting the well-being of those people.

3. Work on clinical or translational research involving big data. For this RFA, big data are defined as:

   **Big data** are data that meet at least two of the four v’s: (1) high volume, (2) high velocity, (3) high variety, and (4) face veracity issues.

4. Research the opioid epidemic, as NIGMS has identified this as a priority area for funding.

5. Employ robust use of Advance-CTR Service Cores.

6. Are women, underrepresented minorities, and/or representative of Advance-CTR’s partner institutions (Brown University, University of Rhode Island, Lifespan, Care New England, and the Providence VA Medical Center).

**AWARDEE AND MENTOR RESPONSIBILITIES**

Investigators and mentor(s) will be expected to meet on a regular, pre-specified basis to review progress in the goals of the application. A mentorship plan must be established and submitted with the mentor(s) letter of support at the time of application. The mentorship plan should address:

- A communications strategy that fosters consistent and intensive interactions to ensure completion of the project and any relevant training.
- The nature and frequency of the interaction between the mentor(s) and investigators for the duration of the award.
- How the training plan supports the proposed research.

**Awardee Responsibilities**

Investigators selected for a Pilot Project award will be required to:

1. Obtain IRB and IACUC approval, as applicable, before funding can be awarded, no later than March 15, 2019. Applicants are strongly encouraged to have these processes underway at the time of application.
2. Present a seminar describing the project and results at an Advance-CTR Seminar Series session as well as, if invited, at the Advance-CTR External Advisory Committee Meeting.
3. Present a poster at the RI NIH IDeA Symposium and a talk, if invited.
4. Present a formal year-end report within one month of funding end.
5. Complete quarterly progress reports.
6. Complete a formal year-end report within one month of funding end.
7. Complete an Advance-CTR survey at the end of the funding year.
8. Acknowledge sponsorship from Advance-CTR supported by the IDeA-CTR grant (U54GM115677) in all research publications during the performance period. Future publications related to this research must also acknowledge Advance-CTR sponsorship.
9. Report all presentations, publications, and extramural funding that arise from this award to Advance-CTR.
11. Acquire ORCID identifiers.
12. Utilize Advance-CTR Service Core(s) as outlined in the provided Letter of Support(s) and/or request use of services per each Core’s policy, as appropriate.
13. Respond to Advance-CTR queries for information after the grant ends.

**Mentor Responsibilities**

Mentors will be required to provide the awarded investigators with research guidance toward an independent research career through a planned series of meetings and activities as well as frequent
discussions and guidance as needed. Mentors are also expected to complete the Advance-CTR Mentoring Training Program (if a mentor has already completed the training, please upload the certificate under “Additional Documents” when submitting a preliminary application or full proposal).

APPLICATION INSTRUCTIONS
To apply for a Pilot Project award, investigators must first submit a Preliminary Application to Advance-CTR. Selected applicants will then be invited to submit full proposals.

Preliminary Application Submission Instructions
Prospective applicants must submit a Preliminary Application through the UFunds online portal no later than Thursday, October 18, 2018 at 5pm ET. Refer to page 1 of this RFA for submission requirements.

Preliminary Applications will be reviewed according to criteria outlined in the Review Process and Selection Criteria section below. Applicants will be notified on or around Friday, November 9, 2018 if they are invited to submit a full proposal.

Full Proposal Submission Instructions
Full proposals are due through UFunds no later than Tuesday, December 18, 2018 at 5pm ET. Advance-CTR will not consider applications that are incomplete. Complete applications must include the following sections:

Proposal Content
Face Page: (PHS 398 Form Page 1)
The Face Page should include Contact PI name, academic title, institution, address, title of project, and the name of the institutional grant management official. (Note: This form does not need to be signed by an institutional official at the time of submission.)

Project Summary, NIH Page 2: (PHS 398 Form Page 2)
The Project Summary should be a succinct and accurate description of the proposed work. State the application's broad, long-term objectives and specific aims, making reference to the health relatedness of the project. Concisely describe the research design and methods for achieving the stated goals. The summary should be informative to other persons working in the same or related fields and, insofar as possible, understandable to a scientifically or technically literate reader. Avoid describing past accomplishments and the use of first person.

Additionally, the following sections of the Project Summary form should be completed:

- **Relevance**: Describe the relevance of this research to public health. Be succinct (using no more than two or three sentences) and use plain language that can be understood by a general, lay audience.
- **Project/Performance Site Primary Location**: Include the information pertinent to the contact PI’s home institution.
- **Additional Project/Performance Site Location**: Include the information pertaining to any additional performance sites. If more than two performance sites will be used, list additional sites on the PHS 398 Project/Performance Site Format Page.
- **Senior Key Personnel**: Include the Contact PI, multi-PI’s (if Category 2), and mentor(s) for the project. Anyone listed in Senior Key Personnel must include a biosketch in the application.

Budget: (PHS 398 Form Page 4)
The anticipated budget period is 5/1/2018 to 4/30/2019. A separate budget must be submitted for each institution requesting support. Together, the budgets must total no more than $37,500 direct costs for Category 1 applications and $75,000 direct costs for Category 2 applications. Indirect costs associated with the direct costs of each budget will be provided to the home institution(s).
PI salary is allowed, but will be reviewed carefully considering the scope of PI roles. Investigators providing effort without salary support are considered cost shared and must obtain a letter from an authorized organizational official (e.g., Director of Sponsored Projects Office) approving the cost share. Please reference the Letters of Support section below.

The below guidelines should be used to complete the PHS 398 budget form for each institution involved:

- **Personnel:** Indicate the investigator’s name on the “PD/PI” line, number of calendar months dedicated to the proposed research, institutional base salary, requested salary, and associated fringe benefits. Investigators not receiving salary support should still be listed in the budget with effort indicated.
- **Consultant Costs:** If consultant costs are budgeted, include the consultant’s rate and total costs.
- **Equipment:** Equipment (durable items valued at $5,000+) is not allowed for this award.
- **Supplies:** Allowable supply costs include computer software necessary for the project, laboratory supplies and services, animal and per diem housing expenses, publication costs, and participant stipends. General office supplies are not allowed for this award.
- **Travel:** Up to $2,000 can be budgeted for travel related to research performance or dissemination of results.
- **Inpatient Care Costs:** Indicate costs related to proposed research, if any.
- **Outpatient Care Costs:** Indicate costs related to proposed research, if any.
- **Other Expenses:** List any other costs itemized by category, if any.
- **Consortium/Contractual Costs:** Include consortium or contractual costs required to accomplish the proposed research, if any.

Upon funding, mentor(s) can request up to $2,000 (shared among all mentors on a project) for research supply costs. The $2,000 should not be included in the budget(s). Salary support for mentors is not allowed, unless the mentor is a multi-PI on a Category 2 project and in a faculty track deemed allowable for support, as outlined above.

Biostatistics and clinical research support service costs will be covered by Advance-CTR as resources are available. Submit a service request for inquiries regarding available services.

**Budget Justification:** (PHS 398 Continuation Format Page)

Provide detailed justifications for all items requested in the budget(s). Separate justifications must be submitted for each institution requesting support.

**Biographical Sketch (5-page maximum):** (Biographical Sketch Format Page, Instructions and Sample)

A NIH-formatted biosketch is required for each investigator and mentor. If you do not have an eRA Commons user name, you must obtain one to include in the biosketch. Biosketches should not exceed 5 pages.

The personal statement in the biosketch should briefly describe why your experience and qualifications make you particularly well-suited for a Pilot Project award. In the Research Funding section, include other grant support and explain the relationship of each grant to the proposed project, including any scientific or budgetary overlap. Please adhere to the NIH guidelines for your biographical sketch.

**Resources:** (PHS 398 Resources Format page)

Describe space, equipment, and other facilities available for the applicants to accomplish this research project. The Resources Format page must be completed for each Performance Site listed on PHS 398 Form Page 2.

**Checklist:** (PHS 398 Checklist Form Page)

Complete Section 3 only, “Facilities and Administrative Costs” using the home institution’s F&A rate.

**Research Plan (6-page maximum):** (PHS 398 Continuation Format Page)

The format of the Research Plan should follow the outline below exactly. Begin each section of the
Research Plan with a section header (e.g., Specific Aims, Significance, etc.).

- **Specific aims:** Describe the goals and objectives of the research project (up to 1 page).
- **Significance:** Include overall significance of the project, including the scientific premise and relevance to health care needs in Rhode Island (up to 0.5 page).
- **Innovation:** Describe both the conceptual and technical innovation of the proposed project (up to 0.5 page).
- **Approach:** Describe the experimental design and methods, including an appropriate analysis plan. Present preliminary data if available (up to 3.5 pages).
  - Up to 0.5 page of the 3.5-page approach should focus on detailing the statistical analysis plan for the proposed project.
- **Timeline:** Include approximate completion dates for the defined specific aims and above outlined awardee responsibilities (up to 0.5 page).

**References**
Provide a bibliography of any references cited in the Research Plan.

**Multiple PD/PI Leadership Plan:** *(PHS 398 Continuation Format Page)*
A multi-PI plan must be included; it should describe the role of each of the PI’s. Investigators may find it helpful to consider the following elements in their plan for collaboration and include those that are relevant to their proposed project:

- Data collection
- Data analysis
- Communication
- Conflict resolution
- Authorship
- Responsibility for regulatory oversight (IRB/IACUC, etc.)
- Responsibility for financial oversight
- Training/supervision of technicians/assistants/trainees
- Change in institution
- Plans for intellectual property resulting from the project

Refer to *Section 5.5.12 PHS 398 Instructions*. Do not exceed 0.5 page.

**Future Funding Plans (500-word maximum, submitted in UFunds)**
Describe plans to submit applications for future funding. This response should not be uploaded, but submitted via the appropriate UFunds query field.

The below table summarizes required proposal content outlined in this section:

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face Page</td>
<td>Provide the requested administrative information.</td>
<td>n/a</td>
</tr>
<tr>
<td>Project Summary</td>
<td>Complete the Project Summary, Relevance, Project/Performance Site Primary Location, and Senior Key Personnel.</td>
<td>n/a</td>
</tr>
<tr>
<td>Budget</td>
<td>Complete Page 4 of the NIH 398 form for each institution requesting support.</td>
<td>n/a</td>
</tr>
<tr>
<td>Budget Justification</td>
<td>Provide clear, succinct justification for each requested budget item for each institution requesting support.</td>
<td>n/a</td>
</tr>
<tr>
<td>Biographical Sketches</td>
<td>Include for all proposed key personnel, including mentors.</td>
<td>5 pages (each)</td>
</tr>
<tr>
<td>Resources</td>
<td>Detail space, equipment, and other resources available for research.</td>
<td>n/a</td>
</tr>
<tr>
<td>Checklist</td>
<td>Complete Section 3 of PHS 398 Resources Format page.</td>
<td>n/a</td>
</tr>
<tr>
<td>Research Plan</td>
<td>6 pages</td>
<td></td>
</tr>
<tr>
<td>Specific Aims</td>
<td>1 page</td>
<td></td>
</tr>
<tr>
<td>Significance &amp; Innovation</td>
<td>Overall significance of the project, including pertinent background information, scientific premise, and relevance to health care needs in Rhode Island.</td>
<td>0.5 page</td>
</tr>
<tr>
<td>Innovation</td>
<td>0.5 page</td>
<td></td>
</tr>
<tr>
<td>Approach</td>
<td>Preliminary data* and research plan, including expected results, alternative approaches, and analysis plan. Include discussion of</td>
<td>3.5 pages</td>
</tr>
</tbody>
</table>
scientific rigor and biological variables. (Note: up to 0.5 page should focus on detailing the statistical analysis plan for the proposed project.)

| Timeline | Indicate dates for completion of Specific Aims, manuscript submission, and extramural grant applications submission. | 0.5 page |
| References | Provide citations for any references used in the Research Plan. | n/a |
| Multiple PI Leadership Plan | Describe the role of each Multi-PI and plans for collaboration. | 0.5 page |
| Future Funding Plans | Describe plans to submit application for future funding. | 500 words |

*Preliminary data are encouraged, but not required.

Regulatory Information
If Human Subjects, Vertebrate Animals, or Biosafety/Safety Agents are used in the proposed research, be sure to address these sections as described below. Be sure to indicate the IRB and IACUC approvals or status as applicable to your proposed research. Human Subjects education certification must be up-to-date and available upon request for Key Personnel.

Human Subjects and Clinical Trial Information
Refer to Supplemental Instructions, Part II Sections 2-5 to complete a Human Subjects Section if human subjects are involved in the proposed research. To determine whether human subjects are involved, complete the "Am I doing Human Subjects Research?" Questionnaire. To help identify whether research that involves the use of human data or biological specimens is human subjects research, refer to this flowchart. If human subjects are not involved but your proposed research involves human specimens and/or data from subjects, you must provide a justification in this section for your claim that no human subjects are involved. Do not use the protection of human subjects section to circumvent the page limits of the Research Strategy.

All human subjects studies must include:
- The Advance-CTR Human Subjects and Clinical Trial Information Form, which can be downloaded from the Advance-CTR website. Complete the form using the built-in instructions.
- The NIH PHS 398 Inclusion Enrollment Report form following NIH instructions. The Inclusion Enrollment Report can be downloaded from the Advance-CTR website.

Vertebrate Animals Section
Refer to Section 5.5.10 PHS 398 Instructions and the Worksheet for Applications Involving Animals. If vertebrate animals are involved, address each point below. Provide a concise, complete description of the animals and proposed procedures. While additional details may be included in the Research Plan, the responses to the four required points must be cohesive and include sufficient detail.

If all or part of the proposed research involving vertebrate animals will take place at alternate sites (such as project/performance or collaborating site(s)), identify those sites and describe the activities at those locations.

Although no specific page limitation applies to this section, be succinct. Failure to address the following four points will result in the application being designated as incomplete and will be grounds for NIGMS to defer approval of the application. The three points are as follows:

1. **Description of Procedures**: Provide a concise description of the proposed procedures to be used that involve vertebrate animals in the work outlined in the "Research Plan" attachment. Identify the species, strains, ages, sex, and total numbers of animals by species, to be used in the proposed work. If dogs or cats are proposed, provide the source of the animals.
2. **Justifications**: Provide justification that the species are appropriate for the proposed research. Explain why the research goals cannot be accomplished using an alternative model (e.g. computational, human, invertebrate, in vitro).
3. **Minimization of Pain and Distress**: Describe the interventions including analgesia, anesthesia,
sedation, palliative care and humane endpoints that will be used to minimize discomfort, distress, pain, and injury.

Do not use the vertebrate animal section to circumvent the page limits of the Research Plan.

**Biosafety/Select Agents**
Refer to Section 5.5.11 PHS 398 Instructions. Indicate Institutional Safety Committee approvals.

**Letters of Support**
1. **Research Administration:**
   a. If the Contact PI is **not employed by Brown University**, a signed Letter of Intent (LOI) from the Contact PI's office of research administration must be included. If the Contact PI is not receiving salary support, the LOI must explicitly approve of the cost share.
   b. For Multi-PI's **not employed by Brown University**, a signed LOI from the PI's Research Administration should be included. If the Multi-PI is not receiving salary support, the LOI must explicitly approve of the cost share.

2. **Department Chair(s):** Letter(s) from the Department Chair(s) and/or supervisor(s) **for each investigator** documenting the availability of protected time for research must be included. If a Brown University PI is not receiving salary support, the letter must explicitly approve cost share.

3. **Mentor(s):** Letter(s) from the mentor(s) agreeing to advise on the conduct of the proposed research and describing plans for mentoring the junior investigator(s) must be included with the application.

4. **Advance-CTR Consultation(s):** Applicants who utilize an Advance-CTR Service Core consultation must include a letter of support from that Core.

**Summary Statement Response (if applicable)**
Applicants who are re-submitting a proposal from a prior Advance-CTR Pilot Projects Program must provide a one-page response (maximum) to the summary statement they received. Please detail how you addressed all previous concerns in your application.

Additionally, please upload the summary statement to UFunds.

**APPLICATION FORMAT**
Applications should follow an abbreviated NIH format with minor modifications. This application requires the use of the most recent version of the PHS 398 Forms.

**Font:** Arial, Helvetica, Palatino Linotype or Georgia typeface and a font size of 11 points or larger must be used. A Symbol font may be used to insert Greek letters or special characters; the font size requirement still applies. A smaller font size may be used for figures, graphs, diagrams, charts, tables, figure legends, and footnotes, but this type must follow the font typeface requirement and be readily legible.

**Margins:** Margins should be 0.5 inch.

**REVIEW PROCESS AND SELECTION CRITERIA**
Reviews of Preliminary Applications will be conducted by the Advance-CTR Pilot Projects Program Steering Committee. Reviewers of the full applications will include the Steering Committee and others who have content area or methods expertise relevant to the individual proposals. All reviewers will be highly qualified faculty from Brown University, University of Rhode Island, and/or affiliated hospitals. Final selections will be made by a Council comprised of Advance-CTR leadership with approval of the Advance-CTR Steering Committee.

Applications will be reviewed using the following criteria:
1. Responsiveness to the RFA, including the relevance to RI health needs and the clinical or translational nature of the research.
2. Scientific impact and soundness of the experimental design, including plans for data analysis.
3. Technical and conceptual innovation.
4. Training and expertise of the (Multi-)PI's and their ability to perform the proposed research.
5. Scientific and mentoring expertise of the mentor(s).
6. Project environment, including facilities and adequacy of the patient population, if applicable.
7. Reasonable and justified budget that is appropriate for the proposed research.
8. Likelihood that the project will lead to external funding.

Funding is dependent upon final review and approval by the Advance-CTR External Advisory Committee and by NIGMS. Since NIGMS requires IACUC and IRB approval PRIOR to funding, applicants are strongly urged to have obtained or commenced the regulatory approval process(es) at the time of submission of the application. IRB and IACUC approvals must be obtained by March 15, 2019 or applicants risk loss of funding. Assistance with IRB and IACUC protocols can be obtained by submitting a service request for a consultation with the Advance-CTR Clinical Research Resources service.

DATES AND DEADLINES

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 18, 2018</td>
<td>Preliminary Application due</td>
</tr>
<tr>
<td>November 9, 2018</td>
<td>Selected applicants invited to submit a Full Proposal</td>
</tr>
<tr>
<td>December 18, 2018</td>
<td>Full Proposal due</td>
</tr>
<tr>
<td>February 21, 2019</td>
<td>Pilot Awards announced (anticipated)</td>
</tr>
<tr>
<td>March 15, 2019</td>
<td>Regulatory approvals must be obtained</td>
</tr>
<tr>
<td>May 1, 2019</td>
<td>Pilot funding begins (anticipated)</td>
</tr>
</tbody>
</table>

QUESTIONS

Address inquiries regarding the Advance-CTR Pilot Projects Program to Joseph Rego, Project Manager, at joseph_rego@brown.edu or 401-863-1165.

Responses to all questions will be available on the Advance-CTR website.